Kakyung Kim

Archives
Log in
Subscribe
October 23, 2026

๐Ÿ“ˆ econ-radar 2026-10-23 ยท CLDN18.2์™€ ADC: ์œ„์•” ํ‘œ์ ์น˜๋ฃŒ์˜ ์ƒˆ ์ง€๋„(Claudin 18.2 ADC in gastric cancer)

๐Ÿ“ˆ econ-radar 2026-10-23 ยท CLDN18.2์™€ ADC: ์œ„์•” ํ‘œ์ ์น˜๋ฃŒ์˜ ์ƒˆ ์ง€๋„(Claudin 18.2 ADC in gastric cancer)

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-23

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’Š GSK Hibsago๊ฐ€ FDA ์Šน์ธ์„ ๋ฐ›์•˜๋‹ค. ๋งŒ์„ฑ Bํ˜• ๊ฐ„์—ผ(CHB) ์น˜๋ฃŒ์—์„œ 30๋…„๊ฐ„ ์ด์–ด์ง„ 'ํ‰์ƒ ๊ฒฝ๊ตฌ ๋ณต์•ฝ' ๋ฐฉ์‹์— ์ฒ˜์Œ์œผ๋กœ ๋Œ€์•ˆ์ด ์ƒ๊ฒผ๋‹ค.

๐Ÿค– Meta๊ฐ€ Q3 ๋งค์ถœ beat($64.6B)์—๋„ 2026๋…„ ์—ฐ๊ฐ„ AI capex ๊ฐ€์ด๋˜์Šค๋ฅผ $135~145B(์•ฝ 187~201์กฐ์›)๋กœ ์ƒํ–ฅํ•˜๋ฉฐ ์žฅ ๋งˆ๊ฐ ํ›„ 11% ํ•˜๋ฝํ–ˆ๋‹ค. Nasdaq๋„ 2.6% ๋ฐ€๋ ธ๋‹ค. AI ์ธํ”„๋ผ ํˆฌ์ž์™€ ์ˆ˜์ตํ™” ์†๋„ ์‚ฌ์ด์˜ ๊ธด์žฅ์ด ๋น…ํ…Œํฌ ์‹ค์  ์‹œ์ฆŒ์˜ ํ•ต์‹ฌ ํ…Œ๋งˆ๋กœ ์˜ฌ๋ผ์„ฐ๋‹ค.

๐Ÿ”ฌ ESMO 2026์ด ์˜ค๋Š˜ ๋งˆ๋“œ๋ฆฌ๋“œ์—์„œ ๊ฐœ๋ง‰ํ–ˆ๋‹ค. ์œ„์•” CLDN18.2 ADC IBI343 Phase 3 OS HR์ด ์ฒซ ๊ณต๊ฐœ๋๊ณ , ๋‚ด์ผ ์˜คํ›„ mRNA ์•”๋ฐฑ์‹  INTerpath-001 Phase 3 HR์ด ๊ณต๊ฐœ๋  ์˜ˆ์ •์ด๋‹ค.

Today's Top 5

Bio

1. GSK Hibsago FDA ์Šน์ธ [ํ›„์†] โ€” ๋งŒ์„ฑ Bํ˜• ๊ฐ„์—ผ ์ตœ์ดˆ ASO ์น˜๋ฃŒ์ œ, ๊ธฐ๋Šฅ์  ์น˜์œ ์œจ 19% vs 0%

GSK์™€ Ionis๊ฐ€ ๊ณต๋™ ๊ฐœ๋ฐœํ•œ bepirovirsen(Hibsago)์ด 10์›” 20์ผ FDA ์Šน์ธ์„ ๋ฐ›์•˜๋‹ค๊ณ  Healio์™€ AJMC๊ฐ€ 10์›” 21์ผ ๋ณด๋„ํ–ˆ๋‹ค. ๋งŒ์„ฑ Bํ˜• ๊ฐ„์—ผ(CHBยทChronic Hepatitis B)์— ๋Œ€ํ•œ ์„ธ๊ณ„ ์ตœ์ดˆ ์•ˆํ‹ฐ์„ผ์Šค ์˜ฌ๋ฆฌ๊ณ ๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ(ASOยทantisense oligonucleotide) ์น˜๋ฃŒ์ œ๋‹ค. ์ ์‘์ฆ์€ HBsAg โ‰ค3,000 IU/mL์˜ ์„ฑ์ธ CHB ํ™˜์ž๋กœ, Phase 3 B-Well 1ยท2์—์„œ ๊ธฐ๋Šฅ์  ์น˜์œ ์œจ(HBsAg ์†Œ์‹ค+ํ•ญ์ฒด ์ „ํ™˜) 19% vs 0%(์œ„์•ฝ)๋ฅผ ๊ธฐ๋กํ–ˆ๋‹ค. ๊ธฐ์กด ๋‰ดํด๋ ˆ์˜ค์‚ฌ์ด๋“œ(t)์œ ์‚ฌ์ฒด ๊ธฐ๋Šฅ์  ์น˜์œ ์œจ ์•ฝ 1%์™€ ๋น„๊ต๋œ๋‹ค. ์ผ๋ณธ PMDA๋Š” 2026๋…„ 8์›” ์„ธ๊ณ„ ์ตœ์ดˆ๋กœ ์ด ์•ฝ์„ ์Šน์ธํ–ˆ๋‹ค. FDA ์šฐ์„ ์‹ฌ์‚ฌยท๋ŒํŒŒ๊ตฌ์น˜๋ฃŒ์ œ(BTD)ยทํŒจ์ŠคํŠธํŠธ๋ž™ 3์ค‘ ์ง€์ •์„ ๋ณด์œ ํ–ˆ๋‹ค.

โ†— Healio(10/21)

Bio

2. ESMO 2026 Day 1 โ€” IBI343 CLDN18.2 ADC ์œ„์•” Phase 3 OS HR ์ฒซ ๊ณต๊ฐœ

Innovent Biologics์˜ IBI343(arcotatug tavatecan)์ด ์˜ค๋Š˜ ESMO 2026 LBA77์—์„œ ์ง„ํ–‰์„ฑ ๋ถˆ์‘์„ฑ ์œ„์•”ยท์œ„์‹๋„์ ‘ํ•ฉ๋ถ€์•” Phase 3 ๋ฐ์ดํ„ฐ๋ฅผ ์ฒ˜์Œ ๊ณต๊ฐœํ–ˆ๋‹ค. CLDN18.2(ํด๋กœ๋”˜18.2ยทClaudin 18.2) ํ‘œ์  ํ•ญ์ฒด-์•ฝ๋ฌผ ์ ‘ํ•ฉ์ฒด(ADC)๋กœ, ์„ธ๊ณ„ ์ตœ์ดˆ CLDN18.2 ADC Phase 3 ์ฃผ์š” ํ‰๊ฐ€๋ณ€์ˆ˜ ๋‹ฌ์„ฑ ์‚ฌ๋ก€๋‹ค. Innovent๋Š” ์ค‘๊ตญ NMPA์— NDA๋ฅผ ์ œ์ถœํ•ด ์ˆ˜๋ฆฌ๋ฐ›์€ ์ƒํƒœ๋‹ค. Takeda๋Š” 2025๋…„ 10์›” IBI363ยทIBI343 ๋“ฑ ๋ณต์ˆ˜ ์—์…‹์„ ํฌํ•จํ•œ ์ตœ๋Œ€ 114์–ต๋‹ฌ๋Ÿฌ(์•ฝ 15์กฐ8,000์–ต์›) ๊ทœ๋ชจ์˜ ๊ธ€๋กœ๋ฒŒ ํŒŒํŠธ๋„ˆ์‹ญ ๊ณ„์•ฝ์„ ์ฒด๊ฒฐํ–ˆ๋‹ค๊ณ  Fierce Biotech๊ฐ€ ์ „ํ–ˆ๋‹ค.

โ†— BioSpace/Innovent

Bio

3. INTerpath-001 LBA1 D-1 โ€” mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹  Phase 3 HR ๋‚ด์ผ 17:30 KST ๊ณต๊ฐœ

Moderna์™€ MSD๊ฐ€ ๊ณต๋™ ๊ฐœ๋ฐœํ•œ ์ธํ‹ฐ์Šค๋ฉ”๋ž€ ์˜คํ† ์  (intismeran autogene)+ํ‚คํŠธ๋ฃจ๋‹ค ๋ณ‘์šฉ์˜ Phase 3 INTerpath-001 ๋ฐ์ดํ„ฐ๊ฐ€ ๋‚ด์ผ(10์›” 24์ผ) ํ•œ๊ตญ ์‹œ๊ฐ„ ์˜คํ›„ 5์‹œ 30๋ถ„ ESMO 2026 LBA1์—์„œ ๊ณต๊ฐœ๋œ๋‹ค. ์™„์ „ ์ ˆ์ œ ๊ณ ์œ„ํ—˜ ํ‘์ƒ‰์ข…(Stage IIB~IV) 1,137๋ช… ๋Œ€์ƒ์œผ๋กœ, 1์ฐจ ๋ฌด์žฌ๋ฐœ์ƒ์กด(RFS)ยท2์ฐจ ์›๊ฒฉ์ „์ด๋ฌด์žฌ๋ฐœ์ƒ์กด(DMFS) ์œ„ํ—˜๋น„(HR)๊ฐ€ ์ฒ˜์Œ ๋‚˜์˜จ๋‹ค. 8์›” 19์ผ topline์—์„œ ํ†ต๊ณ„์  ์œ ์˜+์ž„์ƒ์  ์˜๋ฏธ ๋‹ฌ์„ฑ์„ ํ™•์ธํ–ˆ์œผ๋‚˜ HR ์ˆ˜์น˜๋Š” ๋‚ด์ผ ์ „๊นŒ์ง€ ๊ณต์‹ ๋ฏธ๊ณต๊ฐœ๋‹ค. Phase 2b์—์„œ HR 0.51์„ ๊ธฐ๋กํ•œ ์•ฝ๋ฌผ๋กœ, Moderna๋Š” ๋‚ด์ผ ํˆฌ์ž์ž ์›จ๋น„๋‚˜๋ฅผ ๋™์‹œ ์ง„ํ–‰ํ•œ๋‹ค.

โ†— pharmaphorum

AIMarket

4. Meta Q3 AI capex ์‡ผํฌ โ€” ๋งค์ถœ $64.6B beat, capex $135~145B ์ƒํ–ฅ, AH -11%

Meta Platforms๊ฐ€ 10์›” 22์ผ(ํ˜„์ง€ ์‹œ๊ฐ„) Q3 2026 ์‹ค์ ์„ ๋ฐœํ‘œํ–ˆ๋‹ค. ๋งค์ถœ $64.6B(์•ฝ 89์กฐ5,000์–ต์›)๋กœ ์ปจ์„ผ์„œ์Šค($63.31B)๋ฅผ ์ƒํšŒํ–ˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ 2026๋…„ ์—ฐ๊ฐ„ AI ์ž๋ณธ์ง€์ถœ(capex) ๊ฐ€์ด๋˜์Šค๋ฅผ $135~145B(์•ฝ 187~201์กฐ์›)๋กœ ์ƒํ–ฅํ•˜๋ฉด์„œ ์žฅ ๋งˆ๊ฐ ํ›„ ์ฃผ๊ฐ€๊ฐ€ ์•ฝ 11% ํ•˜๋ฝํ–ˆ๊ณ  Nasdaq ์ง€์ˆ˜๋„ 2.6% ๋ฐ€๋ ธ๋‹ค. Newsquawk๋Š” Non-GAAP EPS $6.67 ๋Œ€๋น„ ๋ณด๋„๋œ GAAP EPS $3.83์˜ ํ˜ผ์žฌ์— ์ฃผ์˜๋ฅผ ์š”์ฒญํ–ˆ๋‹ค. Yahoo Finance๋Š” ์„ธ๊ธˆ ๋ถ€๋‹ด์ด GAAP ์ด์ต์„ ๋ˆŒ๋ €๋‹ค๊ณ  ์ „ํ–ˆ๋‹ค.

โ†— Newsquawk

Macro

5. FOMC D-5 โ€” ๋™๊ฒฐ ํ™•๋ฅ  ~86%, Warsh ์˜์žฅ ์ฒซ ์ธํ”Œ๋ ˆ์ด์…˜ ๊ฒ€์ฆ ๋ฌด๋Œ€

๋ฏธ๊ตญ ์—ฐ๋ฐฉ๊ณต๊ฐœ์‹œ์žฅ์œ„์›ํšŒ(FOMC) ์ •๋ก€ ํšŒ์˜๊ฐ€ 5์ผ ํ›„์ธ 10์›” 28์ผ์ด๋‹ค. FedRateCalc ๊ธฐ์ค€ ์‹œ์žฅ ๋™๊ฒฐ ํ™•๋ฅ ์€ ์•ฝ 86%๋กœ, ํ˜„ ๊ธฐ์ค€๊ธˆ๋ฆฌ(3.75~4.00%)๊ฐ€ ์œ ์ง€๋  ๊ฒƒ์ด๋ผ๋Š” ์ „๋ง์ด ๋‚˜์˜จ๋‹ค. 9์›” ๋น„๋†์—… ์ทจ์—…์ž ์ˆ˜๊ฐ€ 29,000๋ช…์œผ๋กœ ํฌ๊ฒŒ ์ค„์–ด๋“  ์ƒํ™ฉ์—์„œ ๊ณ ์šฉ ๋ƒ‰๊ฐ์ด ๋™๊ฒฐ ๊ทผ๊ฑฐ๋ฅผ ๋’ท๋ฐ›์นจํ•œ๋‹ค. ์ผ€๋นˆ ์›Œ์‹œ(Kevin Warsh) ์˜์žฅ์€ ์ทจ์ž„ ์ดํ›„ ์ฒ˜์Œ์œผ๋กœ ๋ณธ๊ฒฉ์ ์ธ ์ธํ”Œ๋ ˆ์ด์…˜ ๋ฐ์ดํ„ฐ๋ฅผ ์•ž์— ๋‘๊ณ  ์ด๋ฒˆ ํšŒ์˜์—์„œ ๊ธˆ๋ฆฌ ๊ฒฝ๋กœ๋ฅผ ๋ฐœ์–ธํ•œ๋‹ค. Capital.com์€ ์ •์น˜์  ์••๋ฐ•์ด ๊ฐ€์ค‘๋˜๋Š” ์ƒํ™ฉ์—์„œ๋„ ๋™๊ฒฐ ๊ธฐ์กฐ๊ฐ€ ์œ ์ง€๋  ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒํ–ˆ๋‹ค.

โ†— FedRateCalc

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

CLDN18.2๋Š” ์œ„์•” ์„ธํฌ ํ‘œ๋ฉด์— ๋“œ๋Ÿฌ๋‚˜๋Š” ๋‹จ๋ฐฑ์งˆ๋กœ, IBI343 ADC๋Š” ์ด๋ฅผ ํ‘œ์ ํ•ด ๋…์„ฑ ํŽ˜์ด๋กœ๋“œ๋ฅผ ์•”์„ธํฌ ์•ˆ์œผ๋กœ ๋ฐฐ๋‹ฌํ•œ๋‹ค. Phase 3 OS ๋‹ฌ์„ฑ์€ HER2 ์ดํ›„ ์œ„์•”์—์„œ ADC๊ฐ€ ์ƒˆ ํ‘œ์ค€์„ ๋งŒ๋“œ๋Š” ์ฒซ ๋ฒˆ์งธ ๋Œ€๊ทœ๋ชจ ๊ทผ๊ฑฐ๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-23

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-24 ยท mRNA ๊ฐœ์ธ๋งž์ถค ํ•ญ์•”๋ฐฑ์‹ (Personalized mRNA Cancer Vaccine) Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-22 ยท GLP-1 ํŽฉํƒ€์ด๋“œ ์›๋ฃŒ์˜์•ฝํ’ˆ(API) ๊ณต๊ธ‰๋ง
Powered by Buttondown, the easiest way to start and grow your newsletter.